The market is bleeding, but may be you know this quote:
"Bull markets are born on pessimism, grow on skepticism, mature on optimism, and die on euphoria" - Sir John Templeton
So the actual question is, where are we right now? I guess "Euphoria" is actually over and we are on our steady way down to realistic valuations.
Let's talk facts: As of March 31, 2022,...
On 8/17/2021 Canaccord Genuity brokerage Lower Price Target for SESN giving a Buy rating from $7.00 to $3.00.
Sesen Bio (SESN) flagship drug candidate Vicineum, failed to obtain FDA approval, but they will try a second time to get the regulatory go-ahead for the bladder cancer treatment.
buying long term calls could be a strategy for this one. volatility is...
SESN received a preapproval for the dug, Vicineum, but not in its present form. and the market overreacted to it. sold at market prices. and the price went down to 0.86usd, its strongest support.
The FDA has determined that it cannot approve the BLA for Vicineum in its present form and has provided recommendations specific to additional clinical/statistical data...
Took the chart all the way back out to 2015 to find some relevant levels and did a quick fib retracement. Aside from the 236 level being a key point of resistance, in 2015, the area around $5.20 presented an interesting area of high traffic. SESN managed to break through this briefly but as you'll see, it was fleeting after putting in the top that I used as the...
I'll just say that there are a lot of stocks and cryptos reaching breaking points, and they will most likely all do the same thing. I'm seeing plenty of potential for most everything to break to the downside but the bullish charts look strong so that's what I'm going with. This SESN chart looks really good, but it's at the tipping point as we speak.
On the verge of FDA approval for a new product,
multiple analysts recently adjusting price targets to $6 plus.
In a market full of mania, a stock with good fundamentals may get overhyped especially about something as legitimate as FDA approval.
Who's not talking about SESN and ENZC right now???
If FDA approval falls through both stocks will suffer a lot, so be...
Sesen Bio Inc has turned overbought on the 1D chart (RSI = 86.656, MACD = 0.058, ADX = 57.197) after a strong 10 day bullish sequence that broke above both the 1D MA50 and MA200 periods, but remains a buy opportunity as the MACD remains below the 9-month High. On top of that we have an emerging Golden Cross, while the price seems to be still within the...
